Navigation Links
Abide Therapeutics Appoints Dr. Gary O'Neill as Vice President of Biology
Date:10/29/2013

SAN DIEGO, Oct. 29, 2013 /PRNewswire/ -- Abide Therapeutics announces today that Gary O'Neill, Ph.D., has joined Abide Therapeutics as vice president of biology and member of the senior management team. Dr. O'Neill was previously in Boston, where he was responsible for Merck's preclinical drug discovery programs in respiratory, immunology and oncology.

(Logo: http://photos.prnewswire.com/prnh/20130502/LA06084LOGO)

"Dr. O'Neill has more than 20 years of experience advancing drug discovery programs to clinical trials," said Alan Ezekowitz, MBChB, D.Phil., president and CEO of Abide Therapeutics. "His extensive experience as a molecular biologist, in-depth knowledge of multiple disease areas, and proven success in advancing drug candidates from target discovery to clinical trials will drive our research and development programs as we advance a pipeline of novel small molecules targeting the large and therapeutically relevant family of serine hydrolases."

"Abide's ability to selectively and near-universally target the more than 200 members of the serine hydrolase 'superfamily' is a unique platform to extract the therapeutic potential from this enzyme class," said Dr. O'Neill. "I am looking forward to joining the team at Abide as we work to discover and develop novel medicines in many therapeutic areas."

Dr. O'Neill's long-standing career with Merck started in 1990 when he joined as a senior research scientist. His scientific accomplishments lead to leadership positions of increasing responsibility at Merck Frosst Research Laboratories, and by 2006, Dr. O'Neill was executive director and head of biology, where he was responsible for a large research team engaged in the discovery and clinical advancement of innovative small molecule drugs to treat asthma, COPD, inflammation, pain, diabetes, obesity, and cardiovascular indications.

In 2009, Dr. O'Neill became the site lead & executive director in respiratory and immunology and then in 2011 the discovery site head and vice president at the Boston Merck Research Laboratories. Here, he led several compounds to clinical trials and was responsible for the implementation of Merck's preclinical drug discovery programs in asthma and rheumatoid arthritis.

Dr. O'Neill obtained his B.S. and Ph.D. in microbiology and immunology from McGill University and the University of British Columbia, respectively. He did his post-doctoral fellowship in molecular biophysics and biochemistry at Yale University. Since then his successful research career has culminated in numerous prestigious honors, including the Merck Presidential Fellow award and 80 peer-reviewed research publications, which highlight his diverse expertise spanning multiple disease areas.

About Serine Hydrolases
The large family of serine hydrolases are validated but largely under explored as drug targets. These enzymes play a key regulatory role in human physiological processes, such as regulating CNS signaling, digestion, metabolism, inflammation, blood clotting, and life cycle of viruses and pathogens. Thus, the ability to target serine hydrolases has broad therapeutic applications. The proprietary Abide technology platform provides a unique highly selective small molecule collection that specifically targets the common catalytic site of serine hydrolases.  The technology provides a rapid and effective method for target identification and validation.  

About Abide Therapeutics
Abide Therapeutics is focused on developing innovative medicines that target serine hydrolases, one of the largest enzyme classes in nature with validated but mostly untapped therapeutic potential. Serine hydrolases play important regulatory roles in human physiology and disease. Abide has created a proprietary platform, based on technology developed at The Scripps Research Institute by Professors Ben Cravatt and Dale Boger, that specifically targets serine hydrolases with selective small molecules. The ability to target and modulate serine hydrolases has potential to develop new medicines in many therapeutic areas.  Abide is located in San Diego.  To learn more, visit www.abidetx.com


'/>"/>
SOURCE Abide Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Abide Therapeutics Announces Collaboration With Merck to Develop Novel Therapies for Type 2 Diabetes and Metabolic Diseases
2. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
3. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
4. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
5. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
6. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
7. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
8. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
9. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
10. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
11. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ... LLC , and named its founder as Diplomat,s chief ... Tennessee , will operate under Diplomat subsidiary ... offerings for health care partners to include IT outsourcing, ... "In an interoperable world, technology delivers comprehensive insight ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, ... post-acute health care, have expanded their existing home health joint venture through an ... has been operating a joint venture home health company with Asante, delivering clinically ...
(Date:10/12/2017)... ... 12, 2017 , ... Dr. Parsa Mohebi, the Los Angeles ... to the newly revamped Cosmetic Town journal section, featuring articles written ... known as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s ... the 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and ... 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will ... Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph ...
Breaking Medicine News(10 mins):